A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT04036682

Public ClinicalTrials.gov record NCT04036682. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

Study identification

NCT ID: NCT04036682
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Enrollment: 284 participants

Conditions and interventions

Conditions

Interventions

CLN-081 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 30, 2019
Primary completion: Oct 12, 2025
Completion: Mar 30, 2028
Last update posted: Jun 16, 2026

2019 – 2028

United States locations

U.S. sites: 18
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Pacific Cancer Medical Center, Inc	Anaheim	California	92801	—
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
City of Hope at Irvine Lennar	Irvine	California	92618	—
Pacific Shores Medical Group	Long Beach	California	90813	—
AdventHealth	Orlando	Florida	32804	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
University of Michigan Health System - University Hospital	Ann Arbor	Michigan	48109	—
Summit Medical Group PA	Florham Park	New Jersey	07932	—
Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola	New York	11501	—
New York University Langone Health	New York	New York	10016	—
Columbia University Irving Medical Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Gabrail Cancer Center Research	Canton	Ohio	44701	—
Providence Cancer Center	Portland	Oregon	97213	—
Providence Oncology & Hematology Care Clinic-Westside	Portland	Oregon	97225	—
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Virginia Cancer Specialists	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04036682, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 16, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04036682 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →